XC8 in the Treatment of Patients With Bronchial Asthma

Bronchial Asthma Clinical Trial

Official title:

Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess Efficacy, Safety and Optimal Dose of XC8 in Patients With Partly Controlled Bronchial Asthma Receiving Stable Treatment With Low Doses of Inhaled Corticosteroids With or Without Long-acting beta2-agonists

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03450434
• Other study ID #: PULM-XC8-02
• Status: Completed
• Phase: Phase 2
• First received: January 11, 2018
• Last updated: February 27, 2018
• Start date: September 20, 2016
• Est. completion date: September 27, 2017

Study information

• Verified date: February 2018
• Source: PHARMENTERPRISES LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A multicenter, double-blind, randomized, parallel-group comparative Phase II clinical study to assess the efficacy and safety of different doses of XC8 vs Placebo in patients with partly controlled bronchial asthma receiving stable treatment with low doses of inhaled corticosteroids with or without long-acting beta2-agonists during 12-weeks treatment period.

Study design was developed by Pharmenterprises LLS, Russia in cooperation with Eurrus Biotech GmbH, Austria and FGK Clinical Research GmbH, Germany.

The primary objective of the study was to evaluate the effect of different doses of XC8 on change in pre-bronchodilator forced expiratory volume in 1 second (FEV1) (% of predicted value) at Week 12 as compared to baseline at Week 0 vs. Placebo in patients with partly controlled bronchial asthma (BA).

Description:

Twenty Russian centers were approved for participation in this study. Twelve centers were initiated. Patients were enrolled in 12 centers. The study consisted of 4 periods: Screening, Run-In Period, Treatment Period, and Follow-up. All eligible patients were randomized into one of four treatment groups in a ratio of 1:1:1:1.

Treatment group of XC8 2 mg daily (30 patients) Treatment group of XC8 10 mg daily (30 patients) Treatment group of XC8 100 mg daily (30 patients) Treatment group of Placebo (30 patients) The study drug was manufactured by order Pharmenterprises LLS, Russia and Eurrus Biotech GmbH, Austria. During the treatment period (12 weeks) patients took the study drug or Placebo once a day in addition to stable low doses of Inhaled Corticosteroids (ICS) with or without long-acting beta2-agonists (LABA). The follow-up period lasted for 4 weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 120
• Est. completion date: September 27, 2017
• Est. primary completion date: September 27, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Signed the informed consent.

2. Non-smoking men and women aged from 18 to 65 (inclusively).

3. Diagnosis of bronchial asthma that was established not later than 12 months before screening (with mandatory documented evaluation of reversibility of bronchial obstruction assessed by pre- and post-bronchodilator spirometry).

4. Stable therapy with low doses of inhaled corticosteroids with or without long-acting beta2-agonists for at least 3 months prior to screening (Step 2 and 3 according to GINA, 2015 guideline)

5. Symptoms of partly controlled bronchial asthma during four weeks before screening (accordingly to GINA, 2015)

6. Pre-bronchodilator FEV1 is 60-80% of predicted values (inclusive) *

7. Consent of patient to use adequate methods of contraception throughout the study. The adequate methods of contraception are as follows:

• Oral or transdermal contraceptives;

• Condom or diaphragm (barrier method) with spermicide, or

• Intrauterine device.

8. Ability to follow all the requirements of the protocol

Exclusion Criteria:

1. Pregnant or lactating women or women planning pregnancy during the clinical trial; women of childbearing potential (including not sterilized operatively and in postmenopausal period less than 2 years), not using appropriate methods of contraception

2. Smoking within 1 year prior to screening; smoking history of more than 10 pack-year

3. Severe exacerbations or not controlled bronchial asthma for 3 months before screening

4. Chronic Obstructive Pulmonary Disease (COPD) or other lung diseases in addition to bronchial asthma.

5. Inflammatory diseases of mouth

6. Acute infection within 30 days of screening

7. Participation in any clinical trial or use of any investigational product within 30 days of screening

8. Use or indication to take other drugs for treatment of asthma (including antileukotrienes and theophylline extended release), except those permitted by the Protocol

9. Indication for long-term administration of systemic steroidal or non-steroidal anti-inflammatory agents or agents affecting the immune system

10. The need of periodical administration of antihistamines (stable doses of antihistamines for at least 1 month prior to screening and throughout the trial is allowed)

11. Administration of immunosuppressant drugs within 3 months before screening

12. Anaphylaxis, generalized urticaria or angioedema within 1 year prior to screening

13. Known allergy, hypersensitivity or contraindication to receiving XC8 or its components

14. Systemic autoimmune diseases or collagen vascular disease in history.

15. History of malignancy within the past 5 years (except for basal cell carcinoma)

16. Significant cardiac and vascular disease at the present time or for 12 months before screening, including chronic heart failure NYHA Class III or IV; severe arrhythmia requiring therapy with Class Ia, Ib, Ic and Class III antiarrhythmic drug; unstable angina; myocardial infarction; cardiac surgery and CABG; relevant cardiac valves disorders; transient ischemic attack or stroke; uncontrolled arterial hypertension with systolic pressure >180 mm Hg and diastolic pressure >110 mm Hg; pulmonary embolism or deep vein thrombosis.

17. Nephrotic syndrome, moderate and severe chronic renal failure, or significant renal diseases with creatinine level of >1.5 mg/dL (132 µmol/L) in men and >1.4 mg/dL (123 µmol/L) in women or Glomerular Filtration Rate (GFR) < 60 ml/min.

18. HIV, hepatitis B or C, hepatic cirrhosis in history; elevated level of serum aspartate aminotransferase (ASAT) or alanine aminotransferase (ALAT) = 3 times of the upper limit of normal (UNL); elevated common bilirubin = 2 times of UNL at the screening.

19. Anemia (hemoglobin =10.5 g/dL in women and = 11.5 g/dL in men); marked blood loss or sampling not less than one unit of donated blood (= 500 ml) or blood transfusion for previous 12 weeks.

20. Any concomitant disease besides bronchial asthma which is not controlled with stable treatment.

21. Drug or alcohol abuse at the moment of screening or in past which, at the discretion of the investigator, make the patient unfit for the study

22. Inability to read or to write; unwillingness to understand and to follow the procedures of the study protocol; violation of the drug administration regimen or procedure execution that, at the discretion of the Investigator, can impact the results of the study or safety of the patient and interfere his further participation in the study; any other concomitant medical and serious mental conditions which make the patient unfit for participation in the clinical study, limit a validity of receiving of informed consent or can affect ability of the patient to take part in the study

Related Conditions & MeSH terms

• Asthma
• Bronchial Asthma

Intervention

Drug:
• XC8 Oral Tablet
1 tablet of XC8 in a dose according to the treatment group + 2 tablets of placebo (in total 3 tablets) once daily in the morning during 12 weeks of treatment period.
• Placebo Oral Tablet
Placebo (in total 3 tablets) once daily in the morning during 12 weeks of treatment period.

Locations

Country	Name	City	State
Russian Federation	"Allergy and Immunology Center" LLC	Krasnodar
Russian Federation	"Pulmonology Research Institute" FMBA of Russia	Moscow
Russian Federation	Central Research Institute for Tuberculosis at Russian Medical Sciences	Moscow
Russian Federation	Moscow State Medical-Dentist University n.a. A.I. Evdokimov on basis of SMHI "City Hospital ? 62", branch 5	Moscow
Russian Federation	Russian Medical Academy of postgraduate education of Ministry of Healthcare on basis of city's Clinical Hospital ? 52	Moscow
Russian Federation	Ryazan State Medical University	Ryazan'
Russian Federation	"Medical Researches Institute" LLC	Saint Petersburg
Russian Federation	Saint Petersburg State Monetary Healthcare Institution "Nicolaevskiy Hospital"	Saint Petersburg
Russian Federation	State Budgetary Institution of Healthcare "Leningrad region Clinical Hospital"	Saint Petersburg
Russian Federation	State Healthcare Institution "Regional Clinical Hospital"	Saratov
Russian Federation	Federal State Budgetary Educational Institution of the Higher Education "Smolensk State Medical	Smolensk
Russian Federation	State autonomous healthcare institution of Yaroslavl Region "?linical hospital for emergency medical care n. a. N.V. Solovyov"	Yaroslavl,

Sponsors (2)

Lead Sponsor	Collaborator
PHARMENTERPRISES LLC	EURRUS Biotech GmbH

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Forced expiratory volume in 1 second (FEV1) in % of predicted value	To assess changes in FEV1 measured in % through spirometry testing	Week 0 - Week 12
Secondary	Change in Peak expiratory flow rate	To assess daily variability of Peak expiratory flow rate measured in the morning and evening	Week 0 - Week 12
Secondary	Change in Forced expiratory volume in 1 second (FEV1) in absolute values	To assess changes in FEV1 measured through spirometry testing	Week 0 - Week 12
Secondary	Change in FVC in % of predicted	To assess changes in FVC measured through spirometry testing	Week 0 - Week 12
Secondary	Change in FEV1/FVC in % of predicted	To assess changes in FEV1/FVC measured through spirometry testing	Week 0 - Week 12
Secondary	Change in FEF 25-75% in % of predicted	To assess changes in FEF 25-75% measured through spirometry testing	Week 0 - Week 12
Secondary	Change in frequency of using short-acting ß2-agonists	To assess frequency of using short-acting ß2-agonists for resolving BA symptoms recorded in Patient's diary	Week 0 - Week 12
Secondary	Proportion of patients with adequate BA control	To assess number of patients with adequate BA control by GINA 2015 criteria	Week 6 and Week 12
Secondary	Rate of severe exacerbations of BA	To assess number of patients with severe exacerbations of BA by GINA 2015 criteria	Week 0 - Week 12
Secondary	Change of eosinophils level in blood and sputum	To assess change of eosinophils level as part of laboratory analysis	Week 0 - Week 12
Secondary	Change of serum IgE level	To assess change of serum IgE level as part of laboratory analysis	Week 0 - Week 12
Secondary	Change of serum IgG level	To assess change of serum IgG level as part of laboratory analysis	Week 0 - Week 12
Secondary	Change of serum eosinophil cationic protein level	To assess change of serum eosinophil cationic protein as part of laboratory analysis	Screening - Week 0 - Week 12
Secondary	Change of serum tryptase level	To assess changes of serum tryptase as part of laboratory analysis	Screening - Week 0 - Week 12
Secondary	Number of Adverse events and Serious adverse event	Adverse events will be summarized descriptively by treatment arm. Verbatim terms will be mapped to preferred terms and organ systems using the current Medical Dictionary for Regulatory Activities version. For each preferred term, frequency counts and percentages will be calculated by cohort.The nature, severity, seriousness, and relationship to study medication will be summarized for all study subjects	Week 0 - Week 12